Drugs interactions for Tremfya®
- 217 Major drug interactions (including ingredients like Abatacept, Adalimumab, Adenovirus type 7 vaccine live)
- 37 Moderate drug interactions (including ingredients like Anthrax immune globulin human, AstraZeneca COVID-19 Vaccine, Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated))
- 116 Minor drug interactions (including ingredients like Aducanumab, Alirocumab, Allogeneic processed thymus tissue)
370 interactions for Tremfya®The risk or severity of adverse effects can be increased when Abatacept is combined with Guselkumab.The risk or severity of adverse effects can be increased when Adalimumab is combined with Guselkumab.The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Guselkumab.The risk or severity of adverse effects can be increased when Aldesleukin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Anakinra is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Anifrolumab.The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Guselkumab.The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Guselkumab.The risk or severity of adverse effects can be increased when Apremilast is combined with Guselkumab.The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Avacopan.The risk or severity of adverse effects can be increased when Azacitidine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Azathioprine is combined with Guselkumab.The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Guselkumab.The risk or severity of adverse effects can be increased when Baricitinib is combined with Guselkumab.The risk or severity of adverse effects can be increased when Basiliximab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Guselkumab.The risk or severity of adverse effects can be increased when Belatacept is combined with Guselkumab.The risk or severity of adverse effects can be increased when Belimumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Belinostat is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Belumosudil.The risk or severity of adverse effects can be increased when Bendamustine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Betamethasone is combined with Guselkumab.The risk or severity of adverse effects can be increased when Bexarotene is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Bimekizumab.The risk or severity of adverse effects can be increased when Bleomycin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Blinatumomab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Bortezomib is combined with Guselkumab.The risk or severity of adverse effects can be increased when Bosutinib is combined with Guselkumab.The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Brodalumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Budesonide is combined with Guselkumab.The risk or severity of adverse effects can be increased when Busulfan is combined with Guselkumab.The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Guselkumab.The risk or severity of adverse effects can be increased when Canakinumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Capecitabine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Carbamazepine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Carboplatin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Carfilzomib is combined with Guselkumab.The risk or severity of adverse effects can be increased when Carmustine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Guselkumab.The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Guselkumab.The risk or severity of adverse effects can be increased when Chlorambucil is combined with Guselkumab.The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Guselkumab.The risk or severity of adverse effects can be increased when Ciclesonide is combined with Guselkumab.The risk or severity of adverse effects can be increased when Cisplatin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Guselkumab.The risk or severity of adverse effects can be increased when Clofarabine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Corticotropin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Crovalimab.The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Guselkumab.Guselkumab may increase the immunosuppressive activities of Cyclosporine.The risk or severity of adverse effects can be increased when Cytarabine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Dacarbazine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Dactinomycin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Danicopan.The risk or severity of adverse effects can be increased when Dasatinib is combined with Guselkumab.The risk or severity of adverse effects can be increased when Daunorubicin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Decitabine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Deflazacort.The risk or severity of adverse effects can be increased when Desoximetasone is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Deucravacitinib.The risk or severity of adverse effects can be increased when Dexamethasone is combined with Guselkumab.The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Guselkumab.The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Guselkumab.The risk or severity of adverse effects can be increased when Dinutuximab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Diroximel fumarate.The risk or severity of adverse effects can be increased when Docetaxel is combined with Guselkumab.The risk or severity of adverse effects can be increased when Doxorubicin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Eculizumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Efgartigimod alfa.The risk or severity of adverse effects can be increased when Guselkumab is combined with Emapalumab.The risk or severity of adverse effects can be increased when Epirubicin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Eribulin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Etanercept is combined with Guselkumab.The risk or severity of adverse effects can be increased when Etoposide is combined with Guselkumab.The risk or severity of adverse effects can be increased when Everolimus is combined with Guselkumab.The risk or severity of adverse effects can be increased when Floxuridine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Flucytosine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Fludarabine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Guselkumab.The risk or severity of adverse effects can be increased when Flunisolide is combined with Guselkumab.The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Guselkumab.The risk or severity of adverse effects can be increased when Fluocinonide is combined with Guselkumab.The risk or severity of adverse effects can be increased when Fluorometholone is combined with Guselkumab.The risk or severity of adverse effects can be increased when Fluorouracil is combined with Guselkumab.The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Guselkumab.The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Guselkumab.The risk or severity of adverse effects can be increased when Gemcitabine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Glatiramer is combined with Guselkumab.The risk or severity of adverse effects can be increased when Golimumab is combined with Guselkumab.The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Hydrocortisone acetate.The risk or severity of adverse effects can be increased when Guselkumab is combined with Hydrocortisone butyrate.The risk or severity of adverse effects can be increased when Guselkumab is combined with Hydrocortisone succinate.The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Guselkumab.The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Guselkumab.The risk or severity of adverse effects can be increased when Ibrutinib is combined with Guselkumab.The risk or severity of adverse effects can be increased when Idarubicin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Idelalisib is combined with Guselkumab.The risk or severity of adverse effects can be increased when Ifosfamide is combined with Guselkumab.The risk or severity of adverse effects can be increased when Imatinib is combined with Guselkumab.The risk or severity of adverse effects can be increased when Indomethacin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Infliximab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Guselkumab.The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Guselkumab.The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Guselkumab.The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Iptacopan.The risk or severity of adverse effects can be increased when Irinotecan is combined with Guselkumab.The risk or severity of adverse effects can be increased when Ixabepilone is combined with Guselkumab.The risk or severity of adverse effects can be increased when Ixekizumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Lenalidomide is combined with Guselkumab.The risk or severity of adverse effects can be increased when Linezolid is combined with Guselkumab.The risk or severity of adverse effects can be increased when Lomustine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Melphalan is combined with Guselkumab.The risk or severity of adverse effects can be increased when Mepolizumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Methimazole is combined with Guselkumab.The risk or severity of adverse effects can be increased when Methotrexate is combined with Guselkumab.The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Mirikizumab.The risk or severity of adverse effects can be increased when Mitomycin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Mometasone furoate.The risk or severity of adverse effects can be increased when Guselkumab is combined with Monomethyl fumarate.The risk or severity of adverse effects can be increased when Guselkumab is combined with Mosunetuzumab.The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Guselkumab.The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Guselkumab.The risk or severity of immunosuppression can be increased when Guselkumab is combined with Natalizumab.The risk or severity of adverse effects can be increased when Nelarabine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Nilotinib is combined with Guselkumab.The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Guselkumab.Ocrelizumab may increase the immunosuppressive activities of Guselkumab.The risk or severity of adverse effects can be increased when Ofatumumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Olaparib is combined with Guselkumab.The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Ozanimod.The risk or severity of adverse effects can be increased when Paclitaxel is combined with Guselkumab.The risk or severity of adverse effects can be increased when Palbociclib is combined with Guselkumab.The risk or severity of adverse effects can be increased when Panobinostat is combined with Guselkumab.The risk or severity of adverse effects can be increased when Pazopanib is combined with Guselkumab.The risk or severity of adverse effects can be increased when Pegaspargase is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Pegcetacoplan.The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Guselkumab.The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Guselkumab.The risk or severity of adverse effects can be increased when Peginterferon beta-1a is combined with Guselkumab.The risk or severity of adverse effects can be increased when Pemetrexed is combined with Guselkumab.The risk or severity of adverse effects can be increased when Penicillamine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Pentostatin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Phenylalanine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Guselkumab.The risk or severity of adverse effects can be increased when Pirfenidone is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Pirtobrutinib.The risk or severity of adverse effects can be increased when Pomalidomide is combined with Guselkumab.The risk or severity of adverse effects can be increased when Ponatinib is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Ponesimod.The risk or severity of adverse effects can be increased when Pralatrexate is combined with Guselkumab.The risk or severity of adverse effects can be increased when Prednisolone is combined with Guselkumab.The risk or severity of adverse effects can be increased when Prednisone is combined with Guselkumab.The risk or severity of adverse effects can be increased when Procarbazine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Guselkumab.The risk or severity of adverse effects can be increased when Ravulizumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Rilonacept is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Risankizumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Ritlecitinib.The risk or severity of adverse effects can be increased when Rituximab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Ropeginterferon alfa-2b.The risk or severity of adverse effects can be increased when Guselkumab is combined with Rozanolixizumab.The risk or severity of infection can be increased when Rubella virus vaccine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Guselkumab.The risk or severity of adverse effects can be increased when Sarilumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Satralizumab.The risk or severity of adverse effects can be increased when Secukinumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Siltuximab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Siponimod.The risk or severity of adverse effects can be increased when Sirolimus is combined with Guselkumab.The risk or severity of infection can be increased when Smallpox (Vaccinia) Vaccine, Live is combined with Guselkumab.The risk or severity of adverse effects can be increased when Sorafenib is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Spesolimab.The risk or severity of adverse effects can be increased when Streptozocin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Sunitinib is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Sutimlimab.The risk or severity of adverse effects can be increased when Temozolomide is combined with Guselkumab.The risk or severity of adverse effects can be increased when Temsirolimus is combined with Guselkumab.The risk or severity of adverse effects can be increased when Teniposide is combined with Guselkumab.The risk or severity of adverse effects can be increased when Teprotumumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Teriflunomide is combined with Guselkumab.The risk or severity of adverse effects can be increased when Thalidomide is combined with Guselkumab.The risk or severity of adverse effects can be increased when Thiotepa is combined with Guselkumab.The risk or severity of adverse effects can be increased when Tioguanine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Tixocortol is combined with Guselkumab.The risk or severity of adverse effects can be increased when Tocilizumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Topotecan is combined with Guselkumab.The risk or severity of adverse effects can be increased when Trabectedin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Triamcinolone is combined with Guselkumab.The risk or severity of adverse effects can be increased when Trifluridine is combined with Guselkumab.The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Upadacitinib.The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Guselkumab.The risk or severity of adverse effects can be increased when Vedolizumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Vilanterol is combined with Guselkumab.The risk or severity of adverse effects can be increased when Vinblastine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Vincristine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Vinorelbine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Voclosporin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Vorinostat is combined with Guselkumab.The risk or severity of infection can be increased when Yellow fever vaccine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Zidovudine is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Zilucoplan.The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Guselkumab.The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Guselkumab.The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Guselkumab.The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Guselkumab.The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Guselkumab.The risk or severity of adverse effects can be increased when Denosumab is combined with Guselkumab.The risk or severity of immunosuppression can be increased when Guselkumab is combined with Etrasimod.Guselkumab may increase the immunosuppressive activities of Fingolimod.The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Guselkumab.The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Guselkumab.The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Guselkumab.The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Guselkumab.The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Leflunomide.The serum concentration of Guselkumab can be increased when it is combined with Lopinavir.The serum concentration of Magnesium can be decreased when it is combined with Guselkumab.The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Guselkumab.The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Guselkumab.The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Guselkumab.The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Guselkumab.The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Guselkumab.The serum concentration of Pozelimab can be decreased when it is combined with Guselkumab.The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Guselkumab.The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Guselkumab.The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Guselkumab.The therapeutic efficacy of GSK-3844766A can be decreased when used in combination with Guselkumab.The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Guselkumab.The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Guselkumab.The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Guselkumab.Tacrolimus may increase the immunosuppressive activities of Guselkumab.The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Guselkumab.Guselkumab may increase the immunosuppressive activities of Tofacitinib.The risk or severity of neutropenia can be increased when Trastuzumab is combined with Guselkumab.The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Guselkumab.The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Guselkumab.The risk or severity of infection can be increased when Ublituximab is combined with Guselkumab.The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Aducanumab.The risk or severity of adverse effects can be increased when Alirocumab is combined with Guselkumab.The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Amivantamab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Ansuvimab.The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Guselkumab.The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Guselkumab.The risk or severity of adverse effects can be increased when Atezolizumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Atoltivimab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Avelumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Axatilimab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Bamlanivimab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Benralizumab.The risk or severity of adverse effects can be increased when Bevacizumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Bezlotoxumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Brolucizumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Burosumab.The risk or severity of adverse effects can be increased when Caplacizumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Cemiplimab.The risk or severity of adverse effects can be increased when Cetuximab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Cilgavimab.Guselkumab may increase the immunosuppressive activities of Cladribine.Conjugated estrogens may increase the thrombogenic activities of Guselkumab.The risk or severity of adverse effects can be increased when Daratumumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Donanemab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Dostarlimab.The risk or severity of adverse effects can be increased when Dulaglutide is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Dupilumab.The risk or severity of adverse effects can be increased when Durvalumab is combined with Guselkumab.The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Eflapegrastim.The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Guselkumab.The risk or severity of adverse effects can be increased when Elotuzumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Emicizumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Eptinezumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Erenumab.Esterified estrogens may increase the thrombogenic activities of Guselkumab.Estetrol may increase the thrombogenic activities of Guselkumab.Estradiol may increase the thrombogenic activities of Guselkumab.Estradiol acetate may increase the thrombogenic activities of Guselkumab.Estradiol cypionate may increase the thrombogenic activities of Guselkumab.Estradiol valerate may increase the thrombogenic activities of Guselkumab.Estriol may increase the thrombogenic activities of Guselkumab.Estrone sulfate may increase the thrombogenic activities of Guselkumab.Ethinylestradiol may increase the thrombogenic activities of Guselkumab.The risk or severity of adverse effects can be increased when Evolocumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Fanolesomab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Fremanezumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Glofitamab.The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Human cytomegalovirus immune globulin.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Guselkumab.The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Human varicella-zoster immune globulin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Ibalizumab.The risk or severity of adverse effects can be increased when Idarucizumab is combined with Guselkumab.The risk or severity of infection can be increased when Guselkumab is combined with Inebilizumab.The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Guselkumab.The risk or severity of adverse effects can be increased when Ipilimumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Isatuximab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Lanadelumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Lebrikizumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Lecanemab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Loncastuximab tesirine.The risk or severity of adverse effects can be increased when Guselkumab is combined with Maftivimab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Margetuximab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Marstacimab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Mirvetuximab Soravtansine.The risk or severity of adverse effects can be increased when Guselkumab is combined with Mogamulizumab.The risk or severity of adverse effects can be increased when Necitumumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Nemolizumab.The serum concentration of Guselkumab can be decreased when it is combined with Nipocalimab.The risk or severity of adverse effects can be increased when Nivolumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Odesivimab.The risk or severity of adverse effects can be increased when Olaratumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Omalizumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Palivizumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Panitumumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Penpulimab.The risk or severity of adverse effects can be increased when Pertuzumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Polatuzumab vedotin.The risk or severity of adverse effects can be increased when Ramucirumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Ranibizumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Raxibacumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Relatlimab.The risk or severity of adverse effects can be increased when Reslizumab is combined with Guselkumab.Roflumilast may increase the immunosuppressive activities of Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Romosozumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Sacituzumab govitecan.The risk or severity of adverse effects can be increased when Guselkumab is combined with Sotatercept.The risk or severity of adverse effects can be increased when Guselkumab is combined with Sotrovimab.Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Guselkumab.Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Tafasitamab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Telisotuzumab vedotin.The risk or severity of adverse effects can be increased when Teplizumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Tezepelumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Tildrakizumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Tislelizumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Tisotumab vedotin.The risk or severity of adverse effects can be increased when Guselkumab is combined with Tixagevimab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Toripalimab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Tralokinumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Trastuzumab deruxtecan.The risk or severity of adverse effects can be increased when Tremelimumab is combined with Guselkumab.The risk or severity of adverse effects can be increased when Ustekinumab is combined with Guselkumab.The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Guselkumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Vilobelimab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Zanidatamab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Zenocutuzumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Zolbetuximab.
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Tremfya®.
Abatacept
Adalimumab
Adenovirus type 7 vaccine live
Aldesleukin
Alemtuzumab
Anakinra
Anifrolumab
Antilymphocyte immunoglobulin (horse)
Antithymocyte immunoglobulin (rabbit)
Apremilast
Arsenic trioxide
Avacopan
Azacitidine
Azathioprine
Bacillus calmette-guerin substrain tice live antigen
Baricitinib
Basiliximab
Beclomethasone dipropionate
Belatacept
Belimumab
Belinostat
Belumosudil
Bendamustine
Betamethasone
Bexarotene
Bimekizumab
Bleomycin
Blinatumomab
Bortezomib
Bosutinib
Brentuximab vedotin
Brodalumab
Budesonide
Busulfan
Cabazitaxel
Canakinumab
Capecitabine
Carbamazepine
Carboplatin
Carfilzomib
Carmustine
Certolizumab pegol
Chikungunya vaccine (live, attenuated)
Chlorambucil
Chloramphenicol
Ciclesonide
Cisplatin
Clobetasol propionate
Clofarabine
Corticotropin
Cortisone acetate
Crovalimab
Cyclophosphamide
Cyclosporine
Cytarabine
Dacarbazine
Dactinomycin
Danicopan
Dasatinib
Daunorubicin
Decitabine
Deflazacort
Desoximetasone
Deucravacitinib
Dexamethasone
Dexrazoxane
Dimethyl fumarate
Dinutuximab
Diroximel fumarate
Docetaxel
Doxorubicin
Eculizumab
Efgartigimod alfa
Emapalumab
Epirubicin
Eribulin
Etanercept
Etoposide
Everolimus
Floxuridine
Flucytosine
Fludarabine
Fludrocortisone
Flunisolide
Fluocinolone acetonide
Fluocinonide
Fluorometholone
Fluorouracil
Fluticasone furoate
Fluticasone propionate
Gemcitabine
Gemtuzumab ozogamicin
Glatiramer
Golimumab
Human adenovirus e serotype 4 strain cl-68578 antigen
Hydrocortisone acetate
Hydrocortisone butyrate
Hydrocortisone succinate
Hydroxychloroquine
Hydroxyurea
Ibritumomab tiuxetan
Ibrutinib
Idarubicin
Idelalisib
Ifosfamide
Imatinib
Indomethacin
Infliximab
Interferon alfa-2b
Interferon alfa-n3
Interferon beta-1b
Interferon gamma-1b
Iptacopan
Irinotecan
Ixabepilone
Ixekizumab
Lenalidomide
Linezolid
Lomustine
Mechlorethamine
Melphalan
Mepolizumab
Mercaptopurine
Methimazole
Methotrexate
Methylprednisolone
Mirikizumab
Mitomycin
Mitoxantrone
Mometasone furoate
Monomethyl fumarate
Mosunetuzumab
Mycophenolate mofetil
Mycophenolic acid
Natalizumab
Nelarabine
Nilotinib
Obinutuzumab
Ocrelizumab
Ofatumumab
Olaparib
Oxaliplatin
Ozanimod
Paclitaxel
Palbociclib
Panobinostat
Pazopanib
Pegaspargase
Pegcetacoplan
Peginterferon alfa-2a
Peginterferon alfa-2b
Peginterferon beta-1a
Pemetrexed
Penicillamine
Pentostatin
Phenylalanine
Pimecrolimus
Pirfenidone
Pirtobrutinib
Pomalidomide
Ponatinib
Ponesimod
Pralatrexate
Prednisolone
Prednisone
Procarbazine
Propylthiouracil
Ravulizumab
Rilonacept
Risankizumab
Ritlecitinib
Rituximab
Ropeginterferon alfa-2b
Rozanolixizumab
Rubella virus vaccine
Ruxolitinib
Sarilumab
Satralizumab
Secukinumab
Siltuximab
Siponimod
Sirolimus
Smallpox (Vaccinia) Vaccine, Live
Sorafenib
Spesolimab
Streptozocin
Sulfasalazine
Sunitinib
Sutimlimab
Temozolomide
Temsirolimus
Teniposide
Teprotumumab
Teriflunomide
Thalidomide
Thiotepa
Tioguanine
Tixocortol
Tocilizumab
Topotecan
Trabectedin
Trastuzumab emtansine
Triamcinolone
Trifluridine
Typhoid Vaccine Live
Upadacitinib
Varicella zoster vaccine (live/attenuated)
Vedolizumab
Vilanterol
Vinblastine
Vincristine
Vinorelbine
Voclosporin
Vorinostat
Yellow fever vaccine
Zidovudine
Zilucoplan
Anthrax immune globulin human
AstraZeneca COVID-19 Vaccine
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
Clostridium tetani toxoid antigen (formaldehyde inactivated)
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
Denosumab
Etrasimod
Fingolimod
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
Hepatitis A Vaccine
Hepatitis B Vaccine (Recombinant)
Janssen COVID-19 Vaccine
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
Leflunomide
Lopinavir
Magnesium
Measles virus vaccine live attenuated
Moderna COVID-19 Vaccine
Modified vaccinia ankara
Mumps virus strain B level jeryl lynn live antigen
Nuvaxovid
Pozelimab
Rabies immune globulin, human
Rabies virus inactivated antigen, A
Rabies virus inactivated antigen, B
Respiratory syncytial virus vaccine, adjuvanted
Rotavirus vaccine
Sipuleucel-T
Sulfamethoxazole
Tacrolimus
Tick-borne encephalitis vaccine (whole virus, inactivated)
Tofacitinib
Trastuzumab
Typhoid vaccine
Typhoid Vi polysaccharide vaccine
Ublituximab
Varicella zoster vaccine (recombinant)
Aducanumab
Alirocumab
Allogeneic processed thymus tissue
Amivantamab
Ansuvimab
Anthrax vaccine
Asfotase alfa
Atezolizumab
Atoltivimab
Avelumab
Axatilimab
Bamlanivimab
Benralizumab
Bevacizumab
Bezlotoxumab
Brolucizumab
Burosumab
Caplacizumab
Cemiplimab
Cetuximab
Cilgavimab
Cladribine
Conjugated estrogens
Daratumumab
Digoxin Immune Fab (Ovine)
Donanemab
Dostarlimab
Dulaglutide
Dupilumab
Durvalumab
Ebola Zaire vaccine (live, attenuated)
Eflapegrastim
Eftrenonacog alfa
Elotuzumab
Emicizumab
Eptinezumab
Erenumab
Esterified estrogens
Estetrol
Estradiol
Estradiol acetate
Estradiol cypionate
Estradiol valerate
Estriol
Estrone sulfate
Ethinylestradiol
Evolocumab
Fanolesomab
Fremanezumab
Galcanezumab
Glofitamab
Hepatitis B immune globulin
Human cytomegalovirus immune globulin
Human immunoglobulin G
Human Rho(D) immune globulin
Human varicella-zoster immune globulin
Ibalizumab
Idarucizumab
Inebilizumab
Inotuzumab ozogamicin
Ipilimumab
Isatuximab
Lanadelumab
Lebrikizumab
Lecanemab
Loncastuximab tesirine
Maftivimab
Margetuximab
Marstacimab
Mirvetuximab soravtansine
Mogamulizumab
Necitumumab
Nemolizumab
Nipocalimab
Nivolumab
Obiltoxaximab
Odesivimab
Olaratumab
Omalizumab
Palivizumab
Panitumumab
Pembrolizumab
Penpulimab
Pertuzumab
Polatuzumab vedotin
Ramucirumab
Ranibizumab
Raxibacumab
Relatlimab
Reslizumab
Roflumilast
Romosozumab
Sacituzumab govitecan
Sotatercept
Sotrovimab
Synthetic Conjugated Estrogens, A
Synthetic Conjugated Estrogens, B
Tafasitamab
Telisotuzumab vedotin
Teplizumab
Tetanus immune globulin, human
Tezepelumab
Tildrakizumab
Tislelizumab
Tisotumab vedotin
Tixagevimab
Toripalimab
Tralokinumab
Trastuzumab deruxtecan
Tremelimumab
Ustekinumab
Vibrio cholerae CVD 103-HgR strain live antigen
Vilobelimab
Zanidatamab
Zenocutuzumab
Zolbetuximab